Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
February 10, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
February 07, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
January 20, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
December 22, 2021 09:12 ET
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic, Janssen과 연구, 라이선스, 협력 계약 체결하고 치료용 단백질 신약 후보 제조 위해 C1 플랫폼 공급
December 17, 2021 18:45 ET
|
Dyadic International, Inc.
미국 플로리다주 주피터, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 글로벌 바이오테크 기업인 Dyadic International, Inc. (NASDAQ: DYAI)은 Johnson & Johnson 산하 Janssen Pharmaceutical Companies에 소속된 Janssen Biotech, Inc.와 연구,...
ダイアディックが、C1プラットフォームを用いた治療用タンパク質候補の製造に関する研究･ライセンス･共同研究契約をヤンセンと締結したことを発表
December 17, 2021 18:45 ET
|
Dyadic International, Inc.
フロリダ州ジュピタ, Dec. 18, 2021 (GLOBE NEWSWIRE) -- ダイアディック･インターナショナル (Dyadic International, Inc.、以下「ダイアディック」、「同社」) (NASDAQ: DYAI)...
Dyadic宣布与杨森（Janssen）就使用其C1平台生产治疗性蛋白质候选药物达成研究、许可和合作协议
December 17, 2021 18:45 ET
|
Dyadic International, Inc.
佛罗里达州朱庇特, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 专注于进一步创新、应用和部署其专有C1细胞蛋白质生产平台以针对蛋白质疫苗和疗法加速开发、降低生产成本和提高性能的全球生物技术公司Dyadic International, Inc.（以下简称为“Dyadic”、“我们”、“我们的”或“公司”）（纳斯达克股票代码：DYAI）宣布，公司已与强生（Johnson...
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
December 17, 2021 07:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
November 10, 2021 16:00 ET
|
Dyadic International, Inc.
●COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform...
Dyadic Appoints Chief Business Officer to Executive Leadership Team
November 09, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...